Michael Domanski.

Michael E. Farkouh, M.D on & on products review ., Michael Domanski, M.D., Lynn A. Sleeper, Sc.D., Flora S. Siami, M.P.H., George Dangas, M.D., Ph.D., Michael Mack, M.D., Might Yang, M.P.H., David J. Cohen, M.D., Yves Rosenberg, M.D., M.P.H., Scott D. Solomon, M.D., Akshay S. Desai, M.D., M.P.H., Bernard J. Gersh, M.B., Ch.B., D.Phil., Elizabeth A. Magnuson, Sc.D., Alexandra Lansky, M.D., Robin Boineau, M.D., Jesse Weinberger, M.D., Krishnan Ramanathan, M.B., Ch.B., J. Eduardo Sousa, M.D., Ph.D., Jamie Rankin, M.D., Balram Bhargava, M.D., John Buse, M.D., Whady Hueb, M.D., Ph.D., Craig R. Smith, M.D., Victoria Muratov, M.D., M.P.H., Sameer Bansilal, M.D., Spencer King, III, M.D., Michel Bertrand, M.D., and Valentin Fuster, M.D., Ph.D.

The study began in 2007, and the choice of microarray system and design reflects the continuing state of technology available at that time; the choice was not updated during the scholarly study. Two array systems were utilized. One was an Agilent 4-plex array created by the investigators. Each array on the fourplex contains 44,000 oligonucleotide probes covering targeted parts of known disease association , 43 pericentromeric and 41 subtelomeric regions, and a genomic backbone with spacing of just one 1 probe per 75 kb approximately.14 The second system was the Affymetrix Genome-Wide Human being SNP Array 6.0, containing 1.8 million oligonucleotide probes on a single slide.